Home > Cardiology > Reduced risk of major vascular events in lower-extremity PAD patients with rivaroxaban and aspirin

Reduced risk of major vascular events in lower-extremity PAD patients with rivaroxaban and aspirin

Journal
JAMA Cardiology
Reuters Health - 30/09/2020 - Patients with symptomatic lower extremity peripheral artery disease (LE-PAD) are less likely to experience major vascular events if they are treated with a combination of an anticoagulant and an antiplatelet drug versus aspirin alone, a new study suggests. Among the nearly 3,000 patients randomized to either rivaroxaban with aspirin or aspirin alone, the absolute risk reduction of any major vascular event was 4.2% at 30 months with the rivaroxaban-aspirin combination, according to the report published in JAMA Cardiology. "Patients with peripheral artery disease suffer a high risk of future cardiovascular and limb outcomes such as heart attack, stroke, acute limb ischemia, amputation and death," said study coauthor Dr. Sonia Anand, a professor of medicine and epidemiology and a senior scientist at the Population Health Research Institute at McMaster University in Hamilton, Canada. "You can identify the highest risk PAD patients by...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on